يعرض 81 - 100 نتائج من 46,036 نتيجة بحث عن '(((( i largest decrease ) OR ( ((a large) OR (b large)) decrease ))) OR ( a large increases ))', وقت الاستعلام: 1.42s تنقيح النتائج
  1. 81

    Table_1_Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.xlsx حسب Boram Lee (549836)

    منشور في 2021
    "…The genes most frequently altered (> 20%) were (in decreasing order of frequency) CDKN2A, PIM1, CD79B, TP53, MYD88, MYC, BTG2, BTG1, CDKN2B, DTX1, CD58, ETV6, and IRF4. …"
  2. 82
  3. 83

    Supplementary Material for: High-sensitivity Troponin I Measurement in a Large Contemporary Cohort: Implications for Clinical Care حسب Esau D. (20563829)

    منشور في 2025
    "…Male sex, higher HDL-C, higher Hgb A1c, decreasing eGFR, and increasing systolic blood pressure were significant predictors of increased hsTnI. …"
  4. 84
  5. 85
  6. 86
  7. 87
  8. 88
  9. 89
  10. 90

    Fig 2 - حسب Calvin P. Philp (12095878)

    منشور في 2022
  11. 91

    Fig 3 - حسب Calvin P. Philp (12095878)

    منشور في 2022
  12. 92

    DataSheet_1_Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.xlsx حسب Boram Lee (549836)

    منشور في 2021
    "…The genes most frequently altered (> 20%) were (in decreasing order of frequency) CDKN2A, PIM1, CD79B, TP53, MYD88, MYC, BTG2, BTG1, CDKN2B, DTX1, CD58, ETV6, and IRF4. …"
  13. 93
  14. 94
  15. 95

    A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas حسب L. E. van der Meeren (7490675)

    منشور في 2019
    "…<div><p>Diffuse large B-cell lymphoma—not otherwise specified (DLBCL-NOS) is a large and heterogeneous subgroup of non-Hodgkin lymphoma. …"
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100

    Table 1_Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.docx حسب Dewan Zhao (21547445)

    منشور في 2025
    "…Introduction<p>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. …"